Skip to main content
  • genomeweb
  • 360dx
360Dx
  • RSS Feeds
  • Twitter
  • LinkedIn
  • Forgot your password?
  • Subscribe
  • Business & Policy
      • Business News
      • Research Funding
      • Policy & Legislation
      • Regulatory News
      • Reimbursement
  • Clinical Lab Management
  • Diagnostics
      • Molecular Diagnostics
      • Immunoassays
      • Tissue-Based Testing
      • Clinical Chemistry
      • Hematology/Coagulation
      • Point-of-Care Testing
      • Companion Diagnostics
  • Disease Areas
      • Cancer
      • Infectious Disease
      • Cardiovascular Disease
      • Neurological & Psychological Disease
      • Autoimmune Disease
      • Inherited Disease
      • Reproductive Health
      • Respiratory
      • Gastrointestinal
  • Resources
      • Webinars
      • White Papers
      • Job Listings
      • New Products
      • People in the News
      • Conferences & Events

Main menu

Home › FDA Approves Expanded Use of Agilent Assay as Keytruda CDx for Urothelial Cancer

FDA Approves Expanded Use of Agilent Assay as Keytruda CDx for Urothelial Cancer

Aug 21, 2018

NEW YORK (GenomeWeb) – Agilent Technologies announced today that the US Food and Drug Administration has approved its Dako PD-L1 IHC 22C3 pharmDx assay for expanded use as a companion diagnostic test for Merck's anti-PD1 immunotherapy Keytruda (pembrolizumab) for urothelial carcinoma.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Breaking News

  • Startup Cadex Genomics Raises $1.5M

  • All Breast Cancer Patients Should Receive Multigene Panel Tests, Surgeon Group Says

  • In Brief This Week: BioDirection, Quest Diagnostics, OncoCyte, and More

  • Jefferies Initiates Coverage of CareDx With Buy Rating

  • Decipher Biosciences, Dendreon Pharmaceuticals Ink Prostate Cancer Research Deal

  • Bio-Rad Clinical ddPCR Test, Diagnostic System Get FDA Clearance

What's Popular?

In Regulatory News
  1. Bio-Rad Clinical ddPCR Test, Diagnostic System Get FDA Clearance

  2. Hologic Aptima HIV-1 Assay Receives Dual Claim CE Marking

  3. Bioneer HIV-1 Dx Kit Gets Korea FDA Approval

  4. GenomeDx Biosciences to Pay $2M to Settle Allegations of Improper Medicare Billing

  5. Q&A: OIR Director Timothy Stenzel Discusses Precision Medicine Efforts During First Year at FDA

    Premium

Sponsorships

  • About Us
  • Advertise
  • Contact
  • Jobs
  • Sitemap
Subscribe

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.